|
[1] BRAY F,FERLAY J,SOERJOMATARAM I,et al. Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin,2018,68(6):394-424.
|
|
[2] BOLAND P,WU J. Systemic therapy for hepatocellular carcinoma:Beyond sorafenib[J]. Chin Clin Oncol,2018,7(5):50.
|
|
[3] LIN CL,CHIEN RN,LIN SM,et al. An occult hepatitis B-derived hepatoma cell line carrying persistent nuclear viral DNA and permissive for exogenous hepatitis B virus infection[J].PLo S One,2013,8(5):e65456.
|
|
[4] KNOLLE PA,THIMME R. Hepatic immune regulation and its involvement in viral hepatitis infection[J]. Gastroenterology,2014,146(5):1193-1207.
|
|
[5] IWAI Y,HAMANISHI J,CHAMOTO K,et al. Cancer immunotherapies targeting the PD-1 signaling pathway[J]. J Biomed Sci,2017,24(1):26.
|
|
[6] SIA D,JIAO Y,MARTINEZ-QUETGLAS I,et al. Identification of an immune-specific class of hepatocellular carcinoma,based on molecular features[J]. Gastroenterology,2017,153(3):812-826.
|
|
[7] LIU Z,LIN Y,ZHANG J,et al. Molecular targeted and immune checkpoint therapy for advanced hepatocellular carcinoma[J]. J Exp Clin Cancer Res,2019,38(1):447.
|
|
[8] LIANG SC,LATCHMAN YE,BUHLMANN JE,et al. Regulation of PD-1,PD-L1,and PD-L2 expression during normal and autoimmune responses[J]. Eur J Immunol,2003,33(10):2706-2716.
|
|
[9] CAO YQ,JIN X,SUI SN,et al. Advances of chimeric antigen receptor T-cell immunotherapy combined with immune checkpoint inhibitors in malignancies therapy[J]. Chin J Clin Oncol,2018,45(9):472-476.(in Chinese)曹雅青，金鑫，隋松男，等．嵌合抗原受体T细胞联合免疫检查点抑制剂治疗恶性肿瘤的研究进展[J]．中国肿瘤临床，2018,45(9):472-476.
|
|
[10] CUI YL. Targeted therapy for hepatocellular carcinoma[J].Chin J Dig Surg,2018,17(5):445-451.(in Chinese)崔云龙．肝癌的靶向治疗[J]．中华消化外科杂志，2018,17(5):445-451.
|
|
[11] XU W,LIU K,CHEN M,et al. Immunotherapy for hepatocellular carcinoma:Recent advances and future perspectives[J].Ther Adv Med Oncol,2019,11:1758835919862692.
|
|
[12] HANAHAN D,WEINBERG RA. Hallmarks of cancer:The next generation[J]. Cell,2011,144(5):646-674.
|
|
[13] SWART M,VERBRUGGE I,BELTMAN JB. Combination approaches with immune-checkpoint blockade in cancer therapy[J]. Front Oncol,2016,6:233.
|
|
[14] LARKIN J,CHIARION-SILENI V,GONZALEZ R,et al. Combined Nivolumab and Ipilimumab or monotherapy in untreated melanoma[J]. N Engl J Med,2015,373(1):23-34.
|
|
[15] KELLEY RK,ABOU-ALFA GK,BENDELL JC,et al. PhaseⅠ/Ⅱstudy of durvalumab and tremelimumab in patients with unresectable hepatocellular carcinoma(HCC):PhaseⅠsafety and efficacy analyses[J]. J Clin Oncol,2017,35(15 Suppl):4073.
|
|
[16] YUAN GQ,MO CJ,ZHANG ZC. Clinical effect of TACE combined with radiofrequency ablation in the treatment of primary liver cancer[J]. Clin J Med Offic,2019,47(10):1126-1127.(in Chinese)袁广庆，莫灿均，张志成．肝动脉化疗栓塞联合射频消融治疗原发性肝癌临床疗效观察[J]．临床军医杂志，2019,47(10):1126-1127.
|
|
[17] GRETEN TF,SANGRO B. Targets for immunotherapy of liver cancer[J]. J Hepatol,2017.[Online ahead of print]
|
|
[18] LEE S,KIM H,JI Y,et al. Evaluation of hepatic toxicity after repeated stereotactic body radiation therapy for recurrent hepatocellular carcinoma using deformable image registration[J].Sci Rep,2018,8(1):16224.
|
|
[19] ABUODEH Y,VENKAT P,KIM S. Systematic review of case reports on the abscopal effect[J]. Curr Probl Cancer,2016,40(1):25-37.
|
|
[20] LENCIONI R,de BAERE T,SOULEN MC,et al. Lipiodol transarterial chemoembolization for hepatocellular carcinoma:A systematic review of efficacy and safety data[J]. Hepatology,2016,64(1):106-116.
|
|
[21] de TONI EN. Immune checkpoint inhibitors:Use them early,combined and instead of TACE?[J]. Gut,2019.[Online ahead of print]
|
|
[22] EL-KHOUEIRY AB,SANGRO B,YAU T,et al. Nivolumab in patients with advanced hepatocellular carcinoma(CheckMate 040):An open-label,non-comparative,phase 1/2 dose escalation and expansion trial[J]. Lancet,2017,389(10088):2492-2502.
|
|
[23] SHI L,CHEN L,WU C,et al. PD-1 blockade boosts radiofrequency ablation-elicited adaptive immune responses against tumor[J]. Clin Cancer Res,2016,22(5):1173-1184.
|
|
[24] DUFFY AG,ULAHANNAN SV,MAKOROVA-RUSHER O,et al.Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma[J]. J Hepatol,2017,66(3):545-551.
|
|
[25] SANGRO B,GOMEZ-MARTIN C,de la MATA M,et al. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C[J]. J Hepatol,2013,59(1):81-88.
|
|
[26] Correction:Gut roundtable meeting paper:Selected recent advances in hepatocellular carcinoma[J]. Gut,2018,67(3):594.
|
|
[27] MARTINS F,SOFIYA L,SYKIOTIS GP,et al. Adverse effects of immune-checkpoint inhibitors:Epidemiology,management and surveillance[J]. Nat Rev Clin Oncol,2019,16(9):563-580.
|
DownLoad: